GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival
GSK’s Zejula-Jemperli combo met its primary endpoint in a trial investigating the drugs in first-line advanced ovarian cancer, but missed on a key secondary endpoint …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
